Paratek Pharmaceuticals

Paratek Pharmaceuticals

Pharmaceutical Manufacturing

Boston, MA 17,902 followers

Developing transformative solutions for patients with infectious diseases and other difficult to treat conditions

About us

Positive outcomes. Positive patient stories. These are our priorities at Paratek Pharmaceuticals. As a commercial-stage biopharmaceutical company, we develop transformative solutions for patients with infectious diseases and other difficult to treat conditions, and we believe that we have the right people, the right knowledge and the right drug to make a difference in patients’ lives. Our Mission To create positive stories for patients, physicians and caregivers based on trust and integrity. To accomplish this, our employees work hard to turn everyday decisions into everyday triumphs that advance our technology and strengthen Paratek. Our Vision To be a leading independent biopharmaceutical company providing novel life-saving products for life-threatening diseases or other public health threats.

Website
http://www.paratekpharma.com
Industry
Pharmaceutical Manufacturing
Company size
51-200 employees
Headquarters
Boston, MA
Type
Public Company
Founded
1996

Locations

Employees at Paratek Pharmaceuticals

Updates

  • According to the CDC, Clostridioides difficile (C. diff) is a serious healthcare-associated infection, affecting nearly 500,000 people annually in the U.S., yet most Americans remain unaware of this infectious disease.  November is C. diff Awareness Month—learn about the symptoms, risk factors, and crucial prevention tips, including the importance of responsible antibiotic use. Discover more from the National Foundation for Infectious Diseases (NFID): https://bit.ly/4hTrGCK  

    • No alternative text description for this image
  • Congratulations to the winners of the 2024 Vivli AMR Surveillance Data Challenge! This challenge plays a critical role in advancing our understanding of antimicrobial resistance (AMR), a global health threat that demands innovation, collaboration, and actionable insights. By leveraging cutting-edge data, these winners are paving the way for new strategies to tackle AMR, ultimately helping to protect patient health worldwide. Paratek is proud to support this important initiative and to stand alongside leaders dedicated to combatting AMR. Together, we’re fostering a future where data-driven solutions bring us closer to overcoming one of healthcare’s biggest challenges. 

  • We’re proud to partner with Biomedical Advanced Research and Development Authority (BARDA) to help enhance national preparedness and response to public health threats through the onshoring of NUZYRA® (omadacycline) manufacturing. This milestone strengthens the U.S. supply of critical medications, supporting resilient healthcare infrastructure and public health.  

    With our support, Paratek Pharmaceuticals completed onshoring the manufacturing for NUZYRA, a therapeutic being evaluated for pulmonary anthrax. Supply chain interruptions, especially during public health emergencies when health care resources may be otherwise constrained, can limit the availability of critical medical countermeasures. Creating a U.S.-based supply chain for NUZYRA helps ensure the antibiotic will be available to help patients during national emergencies. Learn more: https://ow.ly/qNqt50U6pEX

    • No alternative text description for this image
  • Paratek Pharmaceuticals has achieved a major milestone! NUZYRA® (omadacycline) now has fully domestic U.S. manufacturing and supply capabilities, reinforcing our commitment to helping enhance national preparedness and response to public health threats. This achievement is part of our partnership with BARDA, helping to ensure a secure, reliable supply of this important medication. Learn more about this news and our continued work to address critical health needs. https://bit.ly/4fMgbLs

    • Paratek Pharma News: NUZYRA® (omadacycline) U.S. onshoring complete
  • Biotech News: Paratek Pharmaceuticals announces positive Top-Line Data from Phase 2b Study in Nontuberculous Mycobacterial (NTM) Abscessus Pulmonary Disease. Read the release: https://bit.ly/3Ce6Opu In a first-of-its-kind Phase 2b study, Paratek's omadacycline showed promising results in patients with Mycobacterium abscessus complex (MABc) pulmonary disease, a serious condition with limited treatment options. Today's news explores how the study demonstrated measurable improvements in symptom severity, quality of life, and negative sputum cultures. 

    • Paratek Pharmaceuticals Announces Positive Top-Line Data from Phase 2b Study of Oral Omadacycline (OMC) in Nontuberculous Mycobacterial (NTM) Abscessus Pulmonary Disease
  • At Paratek, our people are the cornerstone of our success, and Renee Pohle, Senior Manager of Accounting, definitely brings this to life. Since joining in November 2022, Renee has played a vital role in our finance team, managing key financial processes like quarterly and annual reporting and overseeing our financial auditors. Through the complexities of transitioning from a public to a private company, Renee’s leadership and attention to detail helped us seamlessly navigate these changes, ensuring that our financial statements remained accurate and met our new reporting needs. What truly sets Renee apart is her passion for making a difference. After graduating from the Peter T. Paul College of Business and Economics at the University of New Hampshire with a degree in Science in Business Administration, Accounting and Finance, she started her career auditing real estate companies before she pivoted to the biotech and pharmaceutical world. There she found deeper meaning in her work, knowing her efforts contribute to life-saving therapies. We’re proud to have Renee as part of the Paratek family, where she continues to drive success and inspire those around her! #ParatekProud

Similar pages

Browse jobs

Funding

Paratek Pharmaceuticals 5 total rounds

Last Round

Post IPO debt

US$ 60.0M

Investors

CBC Group
See more info on crunchbase